Pharma Friday - June 5, 2026 - Endocrine News
• Exelixis, Inc. announced positive results from a subgroup analysis of the phase 3 CABINET pivotal trial on May 30, 2026. • The trial demonstrated that CABOMETYX (cabozantinib) provided significant improvements in progression-free survival (PFS) compared to a placebo for patients treating neuroendocrine tumors (NET). • These findings are critical as they provide evidence for the efficacy of cabozantinib in a specific patient population struggling with NET.
endocrinenews.endocrine.org